Rental Agreement Made and entered in Jerusalem, on November 12, 2006Rental Agreement • October 21st, 2009 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
Between: Beck-Teck (Jerusalem) Ltd., Company I.D. 511868465 Of 8 Hartum Street, Beck Science Center, Har Hahotzvim, Jerusalem (hereafter "The Lessor") on one hand; and between: BioCancell Therapeutics Ltd., Company I.D. 513597856 (hereafter "The Lessee") on the other hand;
SUBSCRIPTION AND REGISTRATION RIGHTS AGREEMENTSubscription and Registration Rights Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
This Subscription and Registration Rights Agreement (this “Agreement”), dated as of June 22, 2008, is entered into by and between BioCancell Therapeutics Inc., a Delaware corporation (the “Company”), and Clal Biotechnology Industries Ltd. (the “Purchaser”).
ContractOption Agreement • September 6th, 2011 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
ContractEmployment Agreement • June 24th, 2011 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of the date set forth below, by and between BIOCANCELL THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware (the “Parent”), BIOCANCELL THERAPEUTICS LTD., a company organized under the laws of the State of Israel and a fully owned subsidiary of the Parent, (the “Company” and together with the Parent, the “Companies”), and Avi Barak, Israel Identity Number 030557953 of Tidhar 11, Ramat Gan, Israel, Fax: 03-5745871, Email: avi.barak@biocancell.com (the “Employee”) to be effective as of March 1, 2006 (the “Commencement Date”).
CONVENIENCE TRANSLATION FROM HEBREW -Agreement • November 5th, 2010 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
WHEREAS, during the fourth quarter of 2010, the Company intends to publish a shelf offering report in Israel, according to which the Company shall offer to the public units comprising of (i) shares of common stock of the Company; (ii) series 3 warrants; and (iii) series 4 warrants (the “Units” and the “Offering”, respectively)
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made in Jerusalem as of this _ day of November 14, 2005 (the “Effective Date”).
IRREVOCABLE VOTING AGREEMENTIrrevocable Voting Agreement • April 26th, 2010 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
This Irrevocable Voting Agreement (this "Agreement") is made as of November 22, 2009, by and among Clal Biotechnology Industries Ltd. ("CBI"), Prof. Avraham Hochberg ("Hochberg") and Mr. Avi Barak ("Barak") (each of (i) Barak and Hochberg acting together, and (ii) CBI shall be referred to herein as a "Party" and collectively, the "Parties").
AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And betweenBiocancell Therapeutics Inc. • February 2nd, 2009 • Pharmaceutical preparations
Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Fund, a non profit organization incorporated under the Laws of the State of Israel, represented by its authorized representative (the “Fund”);
TERMINATION OF AN IRREVOCABLE VOTING AGREEMENTAn Irrevocable Voting Agreement • September 6th, 2011 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
This termination of the Irrevocable Voting Agreement (“Voting Agreement”) is made as of June 22, 2011 (the "Effective Date"), by and among Clal Biotechnology Industries Ltd. (“CBI”) of 3 Azrieli Center, Triangle Tower, 45th Floor, Tel-Aviv 67023, Israel, Prof. Avraham Hochberg (“Hochberg”) of 23 Israel Eldad St., Jerusalem 93399, Israel, Mr. Avi Barak of 16/65 Rimlat St., Ramat Gan, Israel and Tikcro Technologies Ltd. (“Tikcro”) of 126 Yigal Allon St, Tel Aviv, Israel 67443 (each a “Party” and collectively, the “Parties”).
AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And between The Fund for Medical Research, Development of Infrastructure and Health Services (Hereinafter: “the Fund”)...Biocancell Therapeutics Inc. • February 2nd, 2009 • Pharmaceutical preparations
BioCancell and the Fund shall be hereinafter collectively referred to in this Agreement as “Parties”; each one of which also referred to as “Party”,
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE ISRAELI SECURITIES LAW, 5728-1968, AS AMENDED, THE U.S. SECURITIES ACT OF 1933, AS AMENDED OR UNDER ANY APPLICABLE U.S. STATE SECURITIES LAWS...Biocancell Therapeutics Inc. • December 17th, 2008
THIS IS TO CERTIFY THAT, [_________________] (the “Holder”) is entitled to purchase from the Company up to [__________] fully paid and non-assessable shares of Common Stock of the Company, nominal value US$.0l per share (the “Common Stock”) comprising (i) the Purchased Shares (as such term is defined in the Subscription Agreement to which this Warrant is attached (the “Subscription Agreement”)) and (ii) the number of shares of Common Stock underlying the Convertible Debenture (as such term is defined in the Subscription Agreement), subject to adjustment as set forth herein (the “Warrant Shares”), at an exercise price per Warrant Share equal to US$ [_____] as may be adjusted hereunder (which, for convenience and indication purposes only, was equal to NIS [___] on the relevant date) (the “Exercise Price”), during the period commencing upon the date hereof and terminating upon the lapse of five (5) years following the Closing Date (as such term is defined in the Subscription Agreement) (t
AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And between BCG Oncology P.C. 16620 N 40th St. Suite E Phoenix, Arizona, USA 85032 (Hereinafter: “the Clinical Trial...Biocancell Therapeutics Inc. • December 17th, 2008
BioCancell and the Clinical Trial Site shall be hereinafter collectively referred to in this Agreement as “Parties”; each one of which also referred to as “Party”.
SUBSCRIPTION AND REGISTRATION RIGHTS AGREEMENTSubscription and Registration Rights Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
This Subscription and Registration Rights Agreement (this “Agreement”), dated as of 12 March, 2008, is entered into by and between BioCancell Therapeutics Inc., a Delaware corporation (the “Company”), and Clal Biotechnology Industries Ltd. (the “Purchaser”).
ADDENDUMBiocancell Therapeutics Inc. • December 17th, 2008
This Addendum is made in Jerusalem as of this 22 day of November, 2005 (the “Effective Date”) and is entered in to by and among Yissum the Research Development Company of the Hebrew University of Jerusalem (hereinafter: “Yissum”) and Biocancell Therapeutic Inc., a company incorporated under the laws of the State of Delaware (hereinafter: “DBTI”) and Biocancell Therapeutics Ltd., a company established under the laws of the State of Israel (hereinafter: “DBTL”) (DBTI and DBTL shall collectively be referred to as the “Company”), for the purposes of amending certain provisions in the Exclusive License Agreement executed by Yissum, DBTI and DBTL on November 14, 2005 (hereinafter: the “License Agreement”), all as set forth hereunder.
COOPERATION AND PROJECT FUNDING AGREEMENTCooperation and Project Funding Agreement • December 17th, 2008 • Biocancell Therapeutics Inc. • New York
The ISRAEL-UNITED STATES BINATIONAL INDUSTRIAL RESEARCH AND DEVELOPMENT FOUNDATION, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (hereinafter referred to as the “Foundation”).
EMPLOYMENT AGREEMENTEmployment Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of the date set forth below, by and between BIOCANCELL THERAPEUTICS LTD., a company organized under the laws of the State of Israel, (the “Company”) and Patricia Ohana, Israel Identity Number 15178999 of Peretz Berenstein 6/14, Jerusalem, Email Address pohana@huji.ac.il (the “Employee”) to be effective as of February 1, 2006 (the “Commencement Date”).
Company Plasmid DNA Production AgreementConfidential Treatment • April 7th, 2009 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
BioCancell Therapeutics Ltd a corporation organized and existing under the laws of the State of Israel, with its principal offices located at Beck Science Center, 8 Hartom St, Har Hotzvim, Jerusalem 97775 Israel (hereinafter referred to as “CLIENT”)
EMPLOYMENT AGREEMENTEmployment Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
This employment agreement (the “Agreement”) is effective as of December , 2005 (the “Effective Date”), by and between BioCancell Therapeutics Ltd., an Israeli company with its principal place of business at Hi-Tech Park, Edmond J. Safra Campus, Givat Ram, P.O. Box 39135, Jerusalem, 91390 and its parent, BioCancell Therapeutics Inc., (collectively the “Company”) and Abraham Hochberg, Ph.D., I.D. No. TZ 9181538, of Beit HaArava 40, Jerusalem 93389 (the “Employee”).
DBT BIOPHARMACEUTICALS, INC. OPTION AGREEMENT FOR OPTIONS GRANTED UNDER SECTION 102(b)(2) OF THE ISRAELI INCOME TAX ORDINANCE TO EMPLOYEES, OFFICERS OR DIRECTORS AS 102 CAPITAL GAINS TRACK OPTIONSOption Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
This Share Option Agreement (the “Agreement”) includes the Notice of Share Option Grant attached hereto as Exhibit A (the “Notice of Share Option Grant”), which is incorporated herein by reference and is made and entered into as of the Date of Grant shown in the Notice of Share Option Grant by and between DBT Biopharmaceuticals, Inc. (the “Company”) and the Participant named in the Notice of Share Option Grant.
BIOCANCELL THERAPEUTICS INC. WARRANT To purchase Shares of Common Stock (subject to adjustment) of BIOCANCELL THERAPEUTICS INC. (the “Company”) at a per share price and subject to the terms detailed below VOID AFTER 17:00 p.m. Eastern Standard Time on...Biocancell Therapeutics Inc. • March 30th, 2012 • Pharmaceutical preparations
THIS IS TO CERTIFY THAT ___________ (the “Holder”) is entitled to purchase from the Company up to ___________ (_______) fully paid and non-assessable Common Stock of the Company, nominal value US$.01 per share (the “Common Stock”), at an exercise price equal to NIS 4.25 (the “Exercise Price”), as may be adjusted hereunder, during the period commencing upon the date hereof and terminating upon the lapse of four (4) years following the closing date of the private placement in which this Warrant is issued) (the “Warrant Period”).
ContractEmployment Agreement • October 21st, 2009 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
AMENDMENTBiocancell Therapeutics Inc. • March 31st, 2011 • Pharmaceutical preparations
This Amendment is made as of this 24th day of January 2011, by and between YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”); and
AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And between Meir Medical Center Kfar Saba, Israel (Hereinafter: “the Medical Center”)Biocancell Therapeutics Inc. • December 17th, 2008
BioCancell and the Medical Center shall be hereinafter collectively referred to in this Agreement as “Parties”; each one of which also referred to as “Party”.
Chardan Capital Markets, LLCBiocancell Therapeutics Inc. • November 12th, 2010 • Pharmaceutical preparations
This letter will confirm that notwithstanding the survival provisions reflected in that Termination Letter dated November 8, 2010, terminating that certain Letter Agreement dated October 19, 2010 (“Letter Agreement”) between BioCancell Therapeutics Inc. (“BioCancell”) and Chardan Capital Markets, LLC ("Chardan"), Chardan will not be entitled to receive any fees or monies or other compensation set forth in the Letter Agreement other than the reimbursement of actual out of pocket expenses paid by Chardan.
AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And between The Fund of Medical Research Development of Infrastructure and Health, Hillel Yaffe Medical Center...Biocancell Therapeutics Inc. • February 2nd, 2009 • Pharmaceutical preparations
BioCancell and the Medical Center shall be hereinafter collectively referred to in this Agreement as “Parties”; each one of which also referred to as “Party”.
Company Plasmid DNA Production AgreementMutual Confidential Disclosure Agreement • May 5th, 2009 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
MASTER PRODUCT SALE AGREEMENTMaster Product Sale Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
This MASTER PRODUCT SALE AGREEMENT (this “Agreement”) is entered into as of September 12, 2008 between BioCancell Therapeutics, Ltd., a corporation organized under the laws of the State of Israel, with a principal business address at Beck Science Center, 8 Hartom Street, Har Hotzvim, Jerusalem 97775 Israel (“CUSTOMER”), and VGXI USA, a business entity registered in the state of Texas, having an address at 2700 Research Forest Drive Suite 180, The Woodlands, Texas 77381, (“VGX”) a DBA of VGX International Inc. at 944-1 Daechi-dong, Kangnam-ku, Seoul, Korea, with reference to the following facts:
AGREEMENTAgreement • October 29th, 2010 • Biocancell Therapeutics Inc. • Pharmaceutical preparations
This agreement (the “Agreement”) effective as of October 28, 2010, is made between BioCancell Therapeutics Inc. of 8 Hartom St, Jerusalem, Israel, a company duly organized and existing under the laws of the state of Delaware (the “Company”), and Clal Finance Underwriting Ltd., of 37 Menachem Begin, Tel Aviv, a company duly organized and existing under the laws of the State of Israel (“Clal”). Each of the Company and Clal shall be known as a “Party” and together the “Parties”.
IRREVOCABLE VOTING AGREEMENTIrrevocable Voting Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
This Irrevocable Voting Agreement (this “Agreement”) made as of July 30, 2008, by and among Clal Biotechnology Industries Ltd. (“CBI”) of ______________, Prof. Avraham Hochberg (“Hochberg”) of ________________, Tikero Technologies Ltd. (“Tikero”) of ________________ and Mr. Avi Barak (“Barak”) of ________________ (each a “Party” and collectively, the “Parties”).
Convenience Translation from Hebrew - BioCancell Therapeutics Inc. (the “Company”)Biocancell Therapeutics Inc. • October 7th, 2010 • Pharmaceutical preparations
CONSULTING AGREEMENTConsulting Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
THIS CONSULTING AGREEMENT (this “Agreement”) made as of the 15 day of February, 2007, by and between BioCancell Therapeutics Ltd. a company organized under the laws of the State of Israel company number 51-359785-61 (the “Company”) and Moshe Landsberg, Israel Identity Number 50774041 (the “Consultant”).
AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And between ‘Keren Mechkarim’ of Bnai-Zion Medical Center Haifa, Israel (Hereinafter: “the Medical Center”)Biocancell Therapeutics Inc. • February 2nd, 2009 • Pharmaceutical preparations
BioCancell and the Medical Center shall be hereinafter collectively referred to in this Agreement as “Parties”; each one of which also referred to as “Party”.
AGREEMENT Between BioCancell Therapeutics Ltd. Beck Science Center, 8 Hartom St. Jerusalem 97775, Israel (Hereinafter: “BioCancell”) And between Hadasit Medical Research Services and Development Ltd. Hadassah Ein-Kerem Hospital Jerusalem, Israel...Biocancell Therapeutics Inc. • February 2nd, 2009 • Pharmaceutical preparations
BioCancell and the Medical Center shall be hereinafter collectively referred to in this Agreement as “Parties”; each one of which also referred to as “Party”.
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • December 17th, 2008 • Biocancell Therapeutics Inc.
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390 Israel, Fax: +972-2-658 6689; ( “Yissum”); and
